Radient Enters Into Research Collaboration Agreement With CeTeCancer

Radient Pharmaceuticals (Radient) has entered into a collaboration agreement through its wholly owned subsidiary AMDL Diagnostics (ADI) with CeTeCancer to validate the effectiveness of its Onko-Sure in vitro diagnostic (IVD) cancer test as an early detection and prevention test for lung cancer.

Reportedly, ADI and CeTeCancer will collaborate on a research project entitled “Early Detection and Prevention of Lung Cancer Using Recent Advances in Genomics and Imagen” using the Onko-Sure cancer test kit.

The purpose of the research project is to identify an effective early-detection and prevention program for lung cancer. CeTeCancer will provide clinical samples and perform all clinical testing. The research project is supported by Innova Corfo and will run for 18 months with final results anticipated to be published in early 2011.

Douglas MacLellan, chairman and CEO of Radient, said: “We are delighted to enter into this partnership with a highly innovative scientific group working to detect and potentially prevent the deadly and worldwide spread of lung cancer. The expected results of this project should significantly accelerate the international commercialiSation of Onko-Sure.”